All companies
Visit website
BIOSMART RESEARCH, INC.
OperatingBiosmart Research, Inc.
Retail · Founded 2019
Nutraceutical CBD isolates for professional distribution
Valuation cap ⓘ
$15.0M
As of Dec 2021 · from BioSmart Research Convertible Note 1 · a SAFE/note conversion ceiling, not a priced valuation
Total raised
$53,400
Across 1 round since 2021
Latest share price
$1.00
BioSmart Research Convertible Note 1 offering price
Financials
FY2019–FY2020 · from SEC filings · hover any figure for its source$1.9M
$75K
2019
$53K
−$149K
2020
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2019
FY2020
Income statement
Revenue
$1,873,578
$52,952
Cost of goods sold
$1,497,859
$0
Gross margin
20%
100%
Net income
$74,730
-$149,247
Taxes paid
$0
$0
Balance sheet
Cash
$68,970
$49,777
Accounts receivable
$0
$0
Total assets
$2,472,260
$2,627,387
Short-term debt
$2,314
$113,067
Long-term debt
$112,577
$127,210
Total liabilities
$114,891
$240,277
Other
Headcount
—
5
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps marked$15.0M
Valuation cap
BioSmart Research Convertible Note 1
A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Raised $53.4K / $1.1MInvestors 24Valuation cap $15M
Reg CF annual-report compliance
Delinquent
Filed 0 of 5 annual reports (FY2021–FY2025)
Missing: 2021, 2022, 2023, 2024, 2025
24 investors
holder-count proxy
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
- Form CJun 30, 20210001670254-21-000764EDGAR
Source: ManualCIK 0001869747Share price $1.00
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.